stds-stis-hiv-aids-2017-keynote

2 / 9

Virology research J 2017 Vol 1 Issue 2
Page 10
Notes:
July 26-27, 2017 | Vancouver, Canada
WORLD CONFERENCE ON STDs, STIs & HIV/AIDS
alliedacademies
There have been numerous attempts to develop
therapeutic vaccines to clear virus-infected cells by
activating viral protein-specific cytotoxic T lymphocytes
using many different recombinant viral vectors. The vesicular
stomatitis virus (VSV), one of the rhabdoviruses, offers
an ideal system for prime-boost vaccine vectors. In order
to induce the maximum immune responses, the priming
recombinant viral vector should be antigenically distinct
from the boosting vector to maximize the boost effect since
a priming vaccine vector will induce neutralizing antibodies
which will neutralize the boosting vaccine vector should
one uses the same vector for the prime-boost vaccinations.
Here, we report robust T-cell immune responses and
humoral immune responses when two antigenically distinct
genetically modified VSV vectors are used for prime-boost
immunization. To examine the CD8+ T cell and B cell adaptive
immune responses against the proteins expressed from the
genetically modified M gene variants of rVSV vectors, we
generated rVSVs with HIV-1 gag, env and pol genes. From
the various vaccination regimens tested in animals, priming
with rVSVInd (GML)-gag, rVSVInd(GML)-pol, and rVSVInd(GML)-
env followed with rVSVNJ(GMM)-gag, rVSVNJ(GMM)-pol,
and rVSVNJ(GMM)-env boosting induced the strongest
CD8+ cytotoxic T cell immune responses against the HIV-1
Gag, Pol, and Env proteins. The same vaccination regimen
also induced strong humoral immune responses against the
HIV-1 Gag protein and Env protein. Increasing vaccine doses
up to 109 PFU induced stronger humoral immune responses
against the HIV-1 Gag protein and Env protein. Our results
demonstrated that rVSVInd(GML) priming following with
rVSVNJ(GMM) boosting is the best for optimum adaptive
CD8+ T cell as well as humoral immune responses. Our results
showed that genetically modified dual serotype VSV vectors
with HIV gene inserts are safe and highly efficient in inducing
robust adaptive immune responses. This rVSV-HIV vaccine is
an excellent candidate as therapeutic vaccine to treat HIV-
positive patients.
Speaker Biography
C Yong Kang, PhD, DSc, FRSC, is a Molecular Virologist and Professor of Virology in the
Department of Microbiology and Immunology, Schulich School of Medicine and Den-
tistry at the University of Western Ontario in Canada (1992-Present). He carried out
his Postgraduate studies at McMaster University where he received a PhD in Virology
under the supervision of Professor Ludvik Prevec (1968-1971) and his Post-doctoral
training under Professor Howard Temin at the University of Wisconsin-Madison (1971-
1974). He went on to serve as a Professor of Virology in the Department of Microbi-
ology at the University of Texas, Southwestern Medical School in Dallas, Texas (1974-
1982), Professor and Chairman of the Department of Microbiology and Immunology
at the University of Ottawa, Faculty of Medicine (1982-1992), and Dean of Science at
the University of Western Ontario (1992-1999). He has received numerous prizes such
as the Award of Excellence of the University of Ottawa (1991), Gold Medal for Ilchun
Lecture (1998), Ho-Am Prize in Medicine (1999), the Order of Korea in Science and
Technology (2002), the McMaster University Distinguished Alumni Award for 2007, the
Lifetime Achievement Award from University of Western Ontario (2009), the Queen
Elizabeth II Diamond Jubilee Medal (2012), selected as a Korean-Canadian Diaspora
to Canadian Society by Canadian Government (2013) and the Scientist of the Year
Award from the Korean Federation of Science and Technology (2013). Dr. Kang was
elected as a Life-time Fellow of the Royal Society of Canada Academy of Science (1993)
and an elected Life-time Member of the Korean Academy of Science and Technology
(1997). He continues to serve as a Grant Selection Committee Member for various fed-
eral granting agencies in Canada and the United States. He is a member of the Board
of Directors of numerous research institutions and foundations. He also serves as a
Reviewer for the Journal of Virology, Journal of Infectious Diseases, Virus Research,
Virology, Journal of Biological Chemistry, Journal of Human Virology and Retrovirology,
and Canadian Medical Association Journal.
e:
C Yong Kang
The University of Western Ontario, Canada
Matrix protein gene variants of two serotypes of vesicular stomatitis virus are ideal
viral vectors for prime-boost therapeutic HIV vaccines